{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-24T04:44:28.635Z","profile":{"slug":"cagrilintide","name":"Cagrilintide","aliases":[],"category":"Amylin analog"},"synthesis":{"mechanism":"Cagrilintide is an amylin analog investigated for weight management, both alone and in combinations such as CagriSema. Evidence for the single agent must be separated from evidence for the combination.","evidence":"WPF’s existing atlas includes systematic reviews and network meta-analyses comparing cagrilintide, CagriSema, semaglutide, and other interventions. These syntheses pose different questions and may combine heterogeneous trials; a title or indirect comparison is not proof of relative superiority.","safety":"No published source-linked citation or jurisdiction-specific regulatory record has been promoted into this Directory entry. Combined-treatment results cannot be attributed to cagrilintide alone, and follow-up duration and safety outcomes need separate appraisal.","observationalBoundary":"WPF's separate observational archive may include contributor reports concerning cagrilintide, whether used alone or as part of a combination such as CagriSema. As with every entry in that archive, these de-identified reports can suggest questions but cannot establish causation, efficacy, comparative safety, or event frequency, and single-agent reports should not be conflated with combination-use reports.","openQuestions":"Which direct randomized data isolate cagrilintide’s effect? How do combination results differ from single-agent results across dose and population? What is known about durability and safety beyond the studied follow-up?"},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":26,"evidenceDepth":"depth_target_met","complete":false,"checks":[{"key":"overview","passed":true,"actual":201,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":295,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":262,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":407,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":219,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":26,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":true,"actual":26,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["reviewed_sources","claims"]},"chemistry":{"id":"4beb492b-cff1-4e40-bcfc-18ffd53c340c","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","molecularFormula":"C194H312N54O59S2","molecularWeight":4409,"aminoAcidSequence":null,"smiles":null,"inchi":"InChI=1S/C194H312N54O59S2/c1-19-100(10)151(184(298)233-128(78-98(6)7)189(303)248-75-49-60-137(248)190(304)247-74-48-59-136(247)182(296)243-155(107(17)255)187(301)232-127(86-143(201)262)173(287)238-150(99(8)9)183(297)210-88-146(265)218-129(90-249)176(290)230-126(85-142(200)261)175(289)244-156(108(18)256)191(305)246-73-46-57-134(246)157(202)271)239-181(295)135-58-47-72-245(135)147(266)89-211-161(275)120(79-109-50-36-34-37-51-109)225-171(285)123(82-139(197)258)228-172(286)124(83-140(198)259)229-177(291)130(91-250)235-178(292)131(92-251)234-170(284)122(81-111-87-207-95-212-111)227-164(278)114(56-45-71-209-194(205)206)221-168(282)119(77-97(4)5)224-169(283)121(80-110-52-38-35-39-53-110)226-166(280)116(65-68-149(269)270)219-158(272)101(11)213-167(281)118(76-96(2)3)223-163(277)113(55-44-70-208-193(203)204)220-165(279)115(63-66-138(196)257)222-186(300)153(105(15)253)240-159(273)102(12)214-179(293)132-93-308-309-94-133(180(294)231-125(84-141(199)260)174(288)242-152(104(14)252)185(299)215-103(13)160(274)241-154(106(16)254)188(302)237-132)236-162(276)112(54-42-43-69-195)216-145(264)67-64-117(192(306)307)217-144(263)61-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-62-148(267)268/h34-39,50-53,87,95-108,112-137,150-156,249-256H,19-33,40-49,54-86,88-94,195H2,1-18H3,(H2,196,257)(H2,197,258)(H2,198,259)(H2,199,260)(H2,200,261)(H2,201,262)(H2,202,271)(H,207,212)(H,210,297)(H,211,275)(H,213,281)(H,214,293)(H,215,299)(H,216,264)(H,217,263)(H,218,265)(H,219,272)(H,220,279)(H,221,282)(H,222,300)(H,223,277)(H,224,283)(H,225,285)(H,226,280)(H,227,278)(H,228,286)(H,229,291)(H,230,290)(H,231,294)(H,232,301)(H,233,298)(H,234,284)(H,235,292)(H,236,276)(H,237,302)(H,238,287)(H,239,295)(H,240,273)(H,241,274)(H,242,288)(H,243,296)(H,244,289)(H,267,268)(H,269,270)(H,306,307)(H4,203,204,208)(H4,205,206,209)/t100-,101-,102-,103-,104+,105+,106+,107+,108+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,150-,151-,152-,153-,154-,155-,156-/m0/s1","inchikey":"LDERDVMBIYGIOI-DDPFBLHVSA-N","structureImageUrl":null,"createdAt":"2026-09-23T02:36:53.717Z","updatedAt":"2026-09-23T02:36:53.717Z"},"evidence":[{"id":"529020aa-9529-4576-9eb9-7a15bf2ef78e","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42260119/","evidenceTier":"animal","summary":"Content-verified record concerning Cagrilintide: \"A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.\" Abstract excerpt: Amylin receptor agonists such as cagrilintide represent emerging obesity therapies. To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC). Here we show that cagrilintide regulate","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1038/s42255-026-01539-3","pubmedId":"42260119","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=33, totalMentions=6). Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s42255-026-01539-3","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.398Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"58956942-3e03-44fa-ba50-0ad603255518","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42583410/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.\" Abstract excerpt: Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches. This systematic review and meta-analysis evaluated their efficacy and safety in adults with overweight or obesity. Four databases were searched from i","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1097/ms9.0000000000005353","pubmedId":"42583410","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=97, totalMentions=4). Imported evidence lane: synthesis. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1097/ms9.0000000000005353","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.164Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"4edec209-6409-4f5a-b7aa-2f820ff4cebc","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42180166/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.\" Abstract excerpt: Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of cagrilintide-based therapies in adults with overwe","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s40200-026-01942-3","pubmedId":"42180166","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=92, totalMentions=6). Imported evidence lane: synthesis. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40200-026-01942-3","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.707Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"a6034008-20c4-4cf3-8ba3-4b30c561c4f8","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42744908/","evidenceTier":"animal","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.\" Abstract excerpt: Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obe","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1038/s42255-026-01603-y","pubmedId":"42744908","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: abstract confirms cagrilintide is a primary subject of this combination study; not yet MEDLINE-indexed.. Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s42255-026-01603-y","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:34.344Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"2c7c630a-9895-4264-90c1-07d68838e414","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251856/","evidenceTier":"phase_3","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.\" Abstract excerpt: Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia. We aimed to compare the efficacy and safety of a once per week combination of cagrilintide with semaglutide (CagriSema) versus placebo as an add-on to basal insulin in individuals with type 2 diabetes. This double-blind, parallel-group, r","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/s0140-6736(26)01022-6","pubmedId":"42251856","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=240, totalMentions=17). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(26)01022-6","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.343Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"85e58509-168e-4227-baa5-16cd8947a283","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251859/","evidenceTier":"phase_3","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.\" Abstract excerpt: The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overw","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/s2213-8587(26)00125-7","pubmedId":"42251859","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=28, totalMentions=21). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s2213-8587(26)00125-7","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.418Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"beef6eb4-7519-4c49-ab6d-5dd519799985","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251858/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/s2213-8587(26)00129-4","pubmedId":"42251858","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: brief clinical commentary specifically about cagrilintide-semaglutide; not yet MEDLINE-indexed.. Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s2213-8587(26)00129-4","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:34.669Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"7a4f07a8-ba41-446d-ac98-2c1662f896a1","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cellular loci for cagrilintide action identified.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42260118/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Cellular loci for cagrilintide action identified.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1038/s42255-026-01541-9","pubmedId":"42260118","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: mechanism report specifically about cagrilintide; not yet MEDLINE-indexed.. Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s42255-026-01541-9","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:34.842Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"d281af9e-5ee5-4321-bf77-061f77a26d4c","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41834765/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.\" Abstract excerpt: Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintid","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1111/dom.70667","pubmedId":"41834765","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=183, totalMentions=4). Imported evidence lane: synthesis. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/dom.70667","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.860Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"164836d4-f398-4963-8292-112198e6b081","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42009015/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Cagrilintide: \"Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.\" Abstract excerpt: The combination of cagrilintide and semaglutide has been shown in global studies to induce reductions in bodyweight. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and semaglutide 2·4 mg versus semaglutide 2·4 mg for weight management in an east Asian population. This double-blind, parallel-group, phase 3a trial (REDEFINE 5) was conducted acro","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/s2213-8587(25)00402-4","pubmedId":"42009015","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=19, totalMentions=9). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s2213-8587(25)00402-4","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.092Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"71575b51-81e4-489b-a66f-75267128667b","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251860/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Cagrilintide: \"Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.\" Abstract excerpt: Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of cagrilintide-semaglutide for people with type 2 diabetes inadequately controlled with diet and exercise. REIMAGINE 1 was a randomised, double-blind, parallel-group, phase 3a study carried out a","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/s2213-8587(26)00126-9","pubmedId":"42251860","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=21). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s2213-8587(26)00126-9","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.003Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"a10d8c95-4212-4f1b-92b0-09221d5a8e2c","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42228334/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.\" Abstract excerpt: Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes. Two studies were conducted to assess the effects of renal or hepatic impairment on pharmacokinetics, safety and tolerability following sin","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s40262-026-01654-0","pubmedId":"42228334","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=9). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40262-026-01654-0","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.471Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"7dde64d5-f6b8-43a1-86fc-4343576197bd","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40544432/","evidenceTier":"animal","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.\" Abstract excerpt: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 ","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1056/NEJMoa2502082","pubmedId":"40544432","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=9). Imported evidence lane: preclinical_animal. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmoa2502082","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.563Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"0136ca1e-b813-4ba7-b9e5-ab6e5a4b95b3","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide-Semaglutide in Adults with Overweight or Obesity.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41259764/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide-Semaglutide in Adults with Overweight or Obesity.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1056/nejmc2513141","pubmedId":"41259764","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: trial report specifically about cagrilintide-semaglutide; not yet MEDLINE-indexed.. Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmc2513141","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:34.745Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"a76fba01-f82f-4ad2-9663-5f070637f142","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40628316/","evidenceTier":"animal","summary":"Content-verified record concerning Cagrilintide: \"Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.\" Abstract excerpt: Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for mouse and rat in vivo and in vitro studies of amylin analogues such as cagrilintide. Structurally, 0839 shares 95 % sequence homology with 0833 a","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/j.lfs.2025.123845","pubmedId":"40628316","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=3). Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.lfs.2025.123845","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.616Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"1143b006-9388-4fb1-844c-f5828607a68b","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40544433/","evidenceTier":"animal","summary":"Directly concerns the combination in adults with overweight or obesity; does not isolate cagrilintide alone.","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1056/NEJMoa2502081","pubmedId":"40544433","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Upgraded from an entered/unverified draft to a content-verified citation. Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=93, totalMentions=10). Imported evidence lane: preclinical_animal. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":"This publication addresses Cagrilintide in the specific setting identified in its title.","supportNature":"Screened source-level context; specific outcomes and evidence tier await appraisal.","qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmoa2502081","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T02:12:07.891Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"ead8299c-7f2a-4ebe-8834-55a181b48d1b","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41052437/","evidenceTier":"animal","summary":"Content-verified record concerning Cagrilintide: \"In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.\" Abstract excerpt: GIM/FP/GP: [Formula: see text].","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.7326/annals-25-03745-jc","pubmedId":"41052437","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: journal-club-style synopsis of a specific cagrilintide-semaglutide trial result; not yet MEDLINE-indexed.. Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.7326/annals-25-03745-jc","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:34.918Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"15017b90-ea6a-4db5-9ca4-d0d6ed6e2881","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39279639/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.\" Abstract excerpt: The combination of cagrilintide and semaglutide (CagriSema) is being developed for the treatment of obesity and type 2 diabetes. The objective of this thorough QT study was to confirm that cagrilintide does not result in a clinically relevant prolongation in cardiac repolarization compared with placebo. This was a double-blind study (NCT05804162) in which healthy participants were randomized to ca","authors":null,"publishingOrg":null,"publicationYear":2024,"doi":"10.1111/dom.15951","pubmedId":"39279639","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=19, totalMentions=8). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/dom.15951","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.490Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"424f1afe-d94a-49c8-a233-759bdf408851","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36883831/","evidenceTier":"laboratory","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.\" Abstract excerpt: Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the ","authors":null,"publishingOrg":null,"publicationYear":2024,"doi":"10.1097/CRD.0000000000000513","pubmedId":"36883831","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=170, totalMentions=3). Imported evidence lane: laboratory_mechanistic. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1097/crd.0000000000000513","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.634Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"18ce3838-6b15-4114-85b1-b577ee62d7c3","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39676787/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.\" Abstract excerpt: No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, l","authors":null,"publishingOrg":null,"publicationYear":2024,"doi":"10.4103/ijem.ijem_45_24","pubmedId":"39676787","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=38, totalMentions=6). Imported evidence lane: synthesis. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.4103/ijem.ijem_45_24","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.930Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"1c16339a-2315-46bb-af1e-9ef86ae1d802","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37364590/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Cagrilintide: \"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.\" Abstract excerpt: Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA 1c ) is unknown. This trial assessed the efficacy and safety of co-administered semaglutide with cagrilintide (CagriSema) in participants with type 2 diabetes. This 32-week, multicentre, double-blind, phase 2 trial was conducted across","authors":null,"publishingOrg":null,"publicationYear":2023,"doi":"10.1016/s0140-6736(23)01163-7","pubmedId":"37364590","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=86, totalMentions=14). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(23)01163-7","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.281Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"21f05054-2b4c-435f-b1d1-0f2472b65741","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36242844/","evidenceTier":"animal","summary":"Content-verified record concerning Cagrilintide: \"Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.\" Abstract excerpt: Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. Interestingly, cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone. Another class of long-acting DACRAs exists, namely the KBPs. These are salmon calcitonin-based and have shown preclinical potential; however, how and if they differentiat","authors":null,"publishingOrg":null,"publicationYear":2022,"doi":"10.1016/j.biopha.2022.113842","pubmedId":"36242844","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=7). Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.biopha.2022.113842","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.542Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"4853960f-740c-48a9-960e-45b03669c989","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Cagrilintide plus semaglutide for obesity management.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/33894837/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Cagrilintide plus semaglutide for obesity management.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2021,"doi":"10.1016/s0140-6736(21)00944-2","pubmedId":"33894837","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: pubmed_curated_indexing_confirms_subject (matched: \"cagrilintide\"). Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(21)00944-2","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:43:19.640Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"81e65c0b-b3e1-494f-87dc-abcb7b0939db","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Development of Cagrilintide, a Long-Acting Amylin Analogue.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34288673/","evidenceTier":"insufficient","summary":"Content-verified record concerning Cagrilintide: \"Development of Cagrilintide, a Long-Acting Amylin Analogue.\" Abstract excerpt: A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acti","authors":null,"publishingOrg":null,"publicationYear":2021,"doi":"10.1021/acs.jmedchem.1c00565","pubmedId":"34288673","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: pubmed_curated_indexing_confirms_subject (matched: \"cagrilintide\"). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1021/acs.jmedchem.1c00565","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:43:19.717Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"e0f1f840-cb84-4b17-bb95-c7f489c7406c","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34798060/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Cagrilintide: \"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.\" Abstract excerpt: Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the effects on bodyweight, safety, and tolerability. We conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial at 57","authors":null,"publishingOrg":null,"publicationYear":2021,"doi":"10.1016/s0140-6736(21)01751-7","pubmedId":"34798060","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=61, totalMentions=8). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(21)01751-7","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:47.786Z","updatedAt":"2026-09-23T23:29:29.141Z"},{"id":"54d11dd9-90f7-49d7-a5c1-8b4fb839fa69","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/33894838/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Cagrilintide: \"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.\" Abstract excerpt: Cagrilintide, a long-acting amylin analogue, and semaglutide 2·4 mg, a glucagon-like peptide-1 analogue, are both being investigated as options for weight management. We aimed to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of this drug combination. In this randomised, placebo-controlled, multiple-ascending dose, phase 1b trial, individuals aged 18-55 years with ","authors":null,"publishingOrg":null,"publicationYear":2021,"doi":"10.1016/s0140-6736(21)00845-x","pubmedId":"33894838","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=20). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(21)00845-x","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:28:48.733Z","updatedAt":"2026-09-23T23:29:29.141Z"}],"regulatory":[{"id":"53cbba17-290e-4b3f-a6a3-d6c6f12a34b8","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","jurisdiction":"European Union — EMA","status":"not_approved","approvedIndication":null,"rationale":"No centrally authorized EMA medicine containing cagrilintide was identified in the EMA medicines database as of 2026-09-23. Cagrilintide remains investigational and has not completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.330Z","updatedAt":"2026-09-23T23:29:29.220Z"},{"id":"27e5d727-b171-48cd-b4c2-a5c703b871e9","peptideId":"b50ca8bf-29aa-48fe-afa3-d5301cbe7c08","jurisdiction":"United States — FDA","status":"not_approved","approvedIndication":null,"rationale":"No FDA-approved product containing cagrilintide was identified in the FDA Drugs@FDA database as of 2026-09-23. Cagrilintide remains investigational, including in combination with semaglutide (CagriSema), and has not completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.242Z","updatedAt":"2026-09-23T23:29:29.220Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}